{"id":"suzetrigine-suz","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Paresthesia"}]},"_chembl":{"chemblId":"CHEMBL5314487","moleculeType":"Small molecule","molecularWeight":"473.40"},"_dailymed":{"setId":"f0976da4-1d20-4517-945c-b60ed2f41c12","title":"JOURNAVX (SUZETRIGINE) TABLET, FILM COATED [VERTEX PHARMACEUTICALS INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Suzetrigine selectively inhibits sodium channels on sensory neurons, reducing the propagation of pain signals to the central nervous system. By decreasing neuronal firing in pain pathways, it provides analgesia without the systemic effects associated with non-selective sodium channel blockers. This mechanism makes it particularly suited for localized or systemic pain management.","oneSentence":"Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:16.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain (post-operative pain)"}]},"trialDetails":[{"nctId":"NCT07231419","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-11-21","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":734},{"nctId":"NCT07378865","phase":"PHASE1","title":"Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-02-13","conditions":"Pain","enrollment":12},{"nctId":"NCT06628908","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-10-01","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":1100},{"nctId":"NCT06696443","phase":"PHASE3","title":"Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-12-18","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":455},{"nctId":"NCT06887972","phase":"PHASE4","title":"A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-21","conditions":"Acute Pain","enrollment":100},{"nctId":"NCT06887959","phase":"PHASE4","title":"A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-27","conditions":"Acute Pain","enrollment":47},{"nctId":"NCT07145346","phase":"PHASE4","title":"Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Irvine","startDate":"2025-11-13","conditions":"Rib Fractures","enrollment":80},{"nctId":"NCT07195669","phase":"PHASE4","title":"RCT: Suzetrigine vs Norco for Post-op Pain","status":"NOT_YET_RECRUITING","sponsor":"Jacob Lensing","startDate":"2025-10-01","conditions":"Pain Control","enrollment":76},{"nctId":"NCT05553366","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-10-03","conditions":"Acute Pain","enrollment":1075},{"nctId":"NCT05661734","phase":"PHASE3","title":"A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-01-09","conditions":"Pain","enrollment":258},{"nctId":"NCT05558410","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-10-10","conditions":"Acute Pain","enrollment":1118},{"nctId":"NCT05660538","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-20","conditions":"Diabetic Peripheral Neuropathy","enrollment":194},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT06834009","phase":"PHASE1","title":"A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-10","conditions":"Pain","enrollment":10},{"nctId":"NCT06336096","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-28","conditions":"Pain","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VX-548"],"phase":"marketed","status":"active","brandName":"Suzetrigine (SUZ)","genericName":"Suzetrigine (SUZ)","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels. Used for Acute pain (post-operative pain).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}